Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy (Case Report)

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Vu Anderson N.; Mehta Urmi V.; Israelsen Paul; Ignatius Ou Sai Hong; Browne Andrew W.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: JOURNAL OF OPHTHALMIC AND VISION RESEARCH Year:2022 | Volume:17 | Issue:1 Page(s): 130-134

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy (Case Report)

Author(s)

Keywords

Carcinoma

Choroidal Neoplasm

Multimodal Imaging

Neoplasm Metastasis

Non-small Cell Lung

Osimertinib

Abstract

Purpose: To illustrate the regression of a metastatic lesion through ophthalmic imaging and correlating findings with standard chest imaging and treatment with osimertinib, an oral chemotherapy agent specific to Epidermal Growth Factor Receptor + Non-small Cell Lung Cancer (EGFR+ NSCLC). Case Report: A 63-year-old Asian male presented to ophthalmology with a complaint of left blurry vision. Initial ophthalmic exam revealed a choroidal lesion and imaging results highlighted a spiculated lung mass with brain and bony metastases. Osimertinib was chosen for its specificity and ability to cross the blood–, brain barrier. Follow-up ophthalmic and radiographic imaging were repeated over the course of treatment. Conclusion: After the initiation of osimertinib, ophthalmic and computed tomography imaging highlighted the regression of the ocular metastatic disease and primary malignancy, respectively. Osimertinib is an effective first-line treatment of EGFR+ NSCLC and corresponding metastatic sites. Additionally, ophthalmic imaging can be used to monitor general response to chemotherapy agents when ocular metastasis is identified.

Multimedia

No record.

Cites

No record.

References

No record.

Cite

APA: Copy

Vu, Anderson N., Mehta, Urmi V., Israelsen, Paul, & Ignatius Ou, Sai Hong. (2022). Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy (Case Report). JOURNAL OF OPHTHALMIC AND VISION RESEARCH, 17(1), 130-134. SID. https://sid.ir/paper/987413/en

Vancouver: Copy

Vu Anderson N., Mehta Urmi V., Israelsen Paul, Ignatius Ou Sai Hong. Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy (Case Report). JOURNAL OF OPHTHALMIC AND VISION RESEARCH[Internet]. 2022;17(1):130-134. Available from: https://sid.ir/paper/987413/en

IEEE: Copy

Anderson N. Vu, Urmi V. Mehta, Paul Israelsen, and Sai Hong Ignatius Ou, “Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy (Case Report),” JOURNAL OF OPHTHALMIC AND VISION RESEARCH, vol. 17, no. 1, pp. 130–134, 2022, [Online]. Available: https://sid.ir/paper/987413/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops